NASDAQ:VTGN Vistagen Therapeutics (VTGN) News Today $5.15 -0.04 (-0.77%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$5.08▼$5.2950-Day Range$1.68▼$13.0552-Week Range$1.62▼$24.71Volume144,006 shsAverage Volume787,723 shsMarket Capitalization$48.20 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.0% in Augustamericanbankingnews.com - September 16 at 3:22 AMMaxim Group Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)markets.businessinsider.com - September 13 at 6:13 PMVistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorderfinance.yahoo.com - September 12 at 9:25 AMVistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japanfinance.yahoo.com - September 5 at 5:14 PMVistagen Appoints Cindy Anderson as Chief Financial Officerfinance.yahoo.com - August 22 at 6:07 PMVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - August 15 at 6:40 PMMaxim Group Remains a Buy on VistaGen Therapeutics (VTGN)markets.businessinsider.com - August 12 at 4:04 PMCommodore Capital Buys in for the Long Haul With 20% Vistagen Stake on Promising Phase 3 Data247wallst.com - August 11 at 8:01 PMVistaGen Therapeutics GAAP EPS of -$0.94 misses by $0.08, revenue of $0.17Mseekingalpha.com - August 11 at 2:57 AMSubsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Resultsfinance.yahoo.com - August 11 at 2:57 AMAffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorderfinance.yahoo.com - August 10 at 10:38 AMWhat's Going On With VistaGen Therapeutics Stock?benzinga.com - August 8 at 9:16 PMMaxim Group Upgrades VistaGen Therapeutics (VTGN)msn.com - August 8 at 9:16 PMVistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023finance.yahoo.com - August 8 at 9:16 PMmarketbeat.com - August 8 at 9:57 AMVistaGen Shares Explode After Successful Fasedienol Trialmarketwatch.com - August 8 at 6:14 AMVistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrocketsmsn.com - August 8 at 6:14 AMBiotech Firm Pops 677% on Social Anxiety Spray Trial Successfinance.yahoo.com - August 8 at 6:14 AMSocial anxiety nasal spray study results make Peninsula biotech's stock shoot up more than 600%finance.yahoo.com - August 8 at 6:14 AMWhy Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?investorplace.com - August 7 at 5:12 PMmarketbeat.com - August 7 at 9:42 AMmarketbeat.com - August 7 at 9:34 AMVistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorderfinance.yahoo.com - August 7 at 8:53 AMmarketbeat.com - August 7 at 8:26 AMVistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brainfinance.yahoo.com - July 17 at 8:35 AMVistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Diseasefinance.yahoo.com - July 13 at 6:55 PMVistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Resultsfinance.yahoo.com - June 28 at 8:12 PMVistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023finance.yahoo.com - June 27 at 6:07 PMVistagen Regains Full Compliance with Nasdaq Listing Requirementsfinance.yahoo.com - June 23 at 9:20 AMVistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorderfinance.yahoo.com - June 21 at 10:25 AMVistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migrainefinance.yahoo.com - June 13 at 8:06 AMVistagen's Nasal Spray Shows Efficacy In Menopausal Hot Flashesmarkets.businessinsider.com - June 7 at 2:45 PMVistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashesfinance.yahoo.com - June 7 at 9:44 AMVistagen to Present at Jefferies 2023 Global Healthcare Conferencefinance.yahoo.com - June 6 at 6:41 PMVistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meetingfinance.yahoo.com - June 1 at 4:06 PMVistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meetingfinance.yahoo.com - May 30 at 7:43 PMVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Healthfinance.yahoo.com - May 24 at 10:26 AMVistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conferencefinance.yahoo.com - April 19 at 1:36 PMInvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101marketwatch.com - April 7 at 9:42 AMWhy VistaGen Therapeutics Stock Is Trading Higher Todaybenzinga.com - April 6 at 1:25 PMVistagen Receives New European Patent for AV-101finance.yahoo.com - April 6 at 1:25 PMSocial Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For Itfinance.yahoo.com - March 30 at 7:32 PMFDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorderfinance.yahoo.com - March 30 at 9:31 AMAnalysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)markets.businessinsider.com - March 24 at 5:55 PMVistagen up 17% after Phase 3 data for anxiety candidateseekingalpha.com - March 22 at 1:00 PMVistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorderfinance.yahoo.com - March 22 at 1:00 PMMaxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)markets.businessinsider.com - March 9 at 5:46 PMVistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorderfinance.yahoo.com - March 8 at 9:21 AMVistagen to Present at Cowen 43rd Annual Health Care Conferencefinance.yahoo.com - March 2 at 8:40 AMVistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migrainefinance.yahoo.com - March 1 at 12:37 PM Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address VTGN Media Mentions By Week VTGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTGN News Sentiment▼0.980.49▲Average Medical News Sentiment VTGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTGN Articles This Week▼11▲VTGN Articles Average Week Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADAG News THTX News SLGL News NERV News OTLK News SURF News FIXX News IMUX News CLSD News DYAI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:VTGN) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.